Browse > Article

Novel Oral Anticoagulants for the Treatment of Venous Thromboembolism in Cancer Patients  

Kim, Joo Hee (College of Pharmacy and Institute of Pharmaceutical Science and Technology, Ajou University)
Gwak, Hye Sun (College of Pharmacy and Division of Life and Pharmaceutical Sciences, Ewha Womans University)
Publication Information
Korean Journal of Clinical Pharmacy / v.26, no.4, 2016 , pp. 269-282 More about this Journal
Abstract
Venous thromboembolism, encompassing deep vein thrombosis and pulmonary embolism, has increased in cancer patients and adversely affects their prognosis. Low-molecular-weight heparins are recommended as efficacious and safe anticoagulation treatment in cancer patients. However, in practice, oral anticoagulation is preferred, especially if longterm or extended treatment is necessary. Novel oral anticoagulants have recently emerged as an alternative to the standard therapy owing to the ease of administration, predictable anticoagulation effect without the need of laboratory monitoring, and fewer drug interactions. These new agents have been shown as effective and safe for the management of cancer-associated thrombosis in ongoing head-to-head comparative trials. Here we review the advances and limitation of current anticoagulant therapies.
Keywords
Novel oral anticoagulant; cancer; venous thromboembolism;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Wasserlauf G, Grandi SM, Filion KB, et al. Meta-analysis of rivaroxaban and bleeding risk. Am J Cardiol 2013;112(3):454-60.   DOI
2 Weinz C, Schwarz T, Kubitza D, et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2009;37(5):1056-64.   DOI
3 Beyer-Westendorf J, Forster K, Pannach S, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014;124(6):955-62.   DOI
4 Tamayo S, Frank Peacock W, Patel M, et al. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin Cardiol 2015;38(2):63-8.   DOI
5 Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009;37(1):74-81.   DOI
6 Chang M, Yu Z, Shenker A, et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol 2016;56(5):637-45.   DOI
7 Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012;33(22):2821-30.   DOI
8 Pathak R, Pandit A, Karmacharya P, et al. Meta-analysis on risk of bleeding with apixaban in patients with renal impairment. Am J Cardiol 2015;115(3):323-7.   DOI
9 Harel Z, Sholzberg M, Shah PS, et al. Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. J Am Soc Nephrol 2014;25(3):431-42.   DOI
10 Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369(22):2093-104.   DOI
11 Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 2008;48(12):1411-9.   DOI
12 Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293(3):715-22.   DOI
13 Koretsune Y, Yamashita T, Yasaka M. Evaluation of edoxaban in patients with atrial fibrillation and severe renal impairment. Eur Heart J 2013;34(suppl1):520.   DOI
14 Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166(4):458-64.   DOI
15 Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992;11(3-4):237-48.   DOI
16 Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res 2010;125(6):490-3.   DOI
17 Agnelli G, Eriksson BI, Cohen AT, et al. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. Thromb Res 2009;123(3):488-97.   DOI
18 Mekaj YH, Mekaj AY, Duci SB, et al. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manage 2015;11:967-77.
19 Graff J, Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet 2013;52:243-54.   DOI
20 Mueck W, Stampfuss J, Kubitza D, et al. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 2014; 53(1):1-16.   DOI
21 Caldeira D, Barra M, Santos AT, et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart 2014;100:550-6.   DOI
22 Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361(24):2342-52.   DOI
23 Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12): 1139-51.   DOI
24 Liakoni E, Ratz Bravo AE, Krahenbuhl S. Hepatotoxicity of New Oral Anticoagulants (NOACs). Drug Saf 2015;38(8):711-20.   DOI
25 Hawbaker S. Venous thromboembolism in the cancer population: pathology, risk, and prevention. J Adv Pract Oncol 2012;3(1):23.
26 Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343(25):1846-50.   DOI
27 Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancerassociated venous thrombosis. Blood 2013;122(10):1712-23.   DOI
28 Falanga A and Marchetti M. Anticancer treatment and thrombosis. Thromb Res 2012;129(3):353-9.   DOI
29 Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemostasis 2013;11(11):56-70.   DOI
30 Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31(17):2189-204.   DOI
31 Dogliotti A, Paolasso E, Giugliano RP. Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin. Clin Cardiol 2013;36(2):61-7.   DOI
32 Imberti D, Agnelli G, Ageno W, et al. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica 2008;93(2):273-8.   DOI
33 Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(suppl6):454s-545s.   DOI
34 Rahme E, Feugere G, Sirois C, et al. Anticoagulant use in patients with cancer associated venous thromboembolism: A retrospective cohort study. Thromb Res 2013;131(3):210-7.   DOI
35 Larsen TB, Skjoth F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Br Med J 2016;353:1-9.
36 Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383(9921):955-62.   DOI
37 Wharin C and Tagalakis V. Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants. Blood Rev 2014;28(1):1-8.   DOI
38 Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagulants: opportunities and challenges. Arterioscler. Thromb Vasc Biol 2015; 35(5):1056-65.   DOI
39 van Es N, Di Nisio M, Bleker SM, et al. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost 2015;114(6):1268-76.   DOI
40 Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002;34(1-2):47-54.   DOI
41 Delate T, Witt DM, Ritzwoller D, et al. Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer. Oncologist 2012;17(3):419-27.   DOI
42 Mandala M, Falanga A, Roila F. et al. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011;22(suppl6):vi85-vi92.   DOI
43 Akl EA, Kahale L, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2014;7:1-70.
44 Kakkar AK, Levine M, Pinedo H, et al. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 2003;8(4): 381-8.   DOI
45 Stangier J and Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009;15(suppl1):9S-16S.   DOI
46 Samer CF, Lorenzini KI, Rollason V, et al. Applications of CYP450 Testing in the Clinical Setting. Mol Diagn Ther 2013;17(3):165-84.   DOI
47 Short NJ and Connors JM. New oral anticoagulants and the cancer patient. Oncologist 2014;19(1):82-93.   DOI
48 Stollberger C and Finsterer J. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Herz 2015; 40(2):140-5.   DOI
49 Hellwig T and Gulseth M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants. Ann Pharmacother 2013;47(11):1478-87.   DOI
50 Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011;31(3):326-43.   DOI
51 Mendell J, Zahir H, Matsushima N, et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 2013;13(5):331-42.   DOI
52 Mikkaichi T, Yoshigae Y, Masumoto H, et al. Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition. Drug Metab Dispos 2014;42(4):520-8.   DOI
53 Pare G, Eriksson N, Lehr T, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013;127: 1402-12.
54 Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med 2011;171(14):1285-6.   DOI
55 Raskob GE, van Es N, Segers A, et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, doubledummy trial. Lancet Haematol. 2016;3(8):e379-87.   DOI
56 Young A, Phillips J, Hancocks H, et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thromb Res 2016;140(suppl1):S172-3.
57 Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial. J Thromb Haemost 2015;13(12):2187-91.   DOI
58 Prins MH, Lensing AW, Brighton TA, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol 2014;1(1):e37-46.   DOI
59 Schulman S, Goldhaber SZ, Kearon C, et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost 2015;114(1):150-7.   DOI
60 Sardar P, Chatterjee S, Mukherjee D. Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomized controlled trials. Drugs 2013;73(11):1171-82.   DOI
61 Vedovati MC, Germini F, Agnelli G, et al. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 2015;147(2):475-83.   DOI
62 Altena R, van Roon E, Folkeringa R, et al. Clinical challenges related to novel oral anticoagulants: drug-drug interactions and monitoring. Haematologica 2014;99(2):e26-e27.   DOI
63 Raskob G, Buller H, Prins M, et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost 2013;11(7):1287-94.   DOI
64 Bounameaux H and Camm AJ. Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs 2014;74(11):1209-31.   DOI
65 Parasrampuria DA and Truitt KE. Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. Clin Pharmacokinet 2016; 55(6):641-55.   DOI
66 Stangier J, Stahle H, Rathgen K, et al. No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin. J Thromb Haemost 2007;5(suppl2):W672.
67 Frost CE, Byon W, Song Y, et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol 2015;79(5):838-46.   DOI
68 Vakkalagadda B, Frost C, Byon W, et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa. Am J Cardiovasc Drugs 2016;16(2):119-27.   DOI
69 Hartter S, Koenen-Bergmann M, Sharma A, et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol 2012;74(3):490-500.   DOI
70 Mendell J, Chen S, He L, et al. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults. Clin Drug Invest 2015;35(7):447-53.   DOI
71 Lam MS and Ignoffo RJ. A guide to clinically relevant drug interactions in oncology. J Oncol Pharm Pract 2003;9(2-3):45-85.   DOI
72 Mavrakanas T, Samer CF, Fontana P, et al. Direct oral anticoagulants: efficacy and safety in patient subgroups. Swiss Med Wkly 2015; 145:w14081.
73 Schulman S, Kearon C, Kakkar AK, et al. Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism. N Engl J Med 2013;368(8):709-18.   DOI
74 Dobesh PP and Fanikos J. New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities. Drugs 2014;74(17):2015-32.   DOI
75 Lee AYY, Levine MN, Baker RI, et al. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. N Engl J Med 2003;349(2):146-53.   DOI
76 Becattini C and Agnelli G. Treatment of venous thromboembolism with new anticoagulant agents. J Am Coll Cardiol 2016;67(16):1941-55.   DOI
77 Piatek C, O’Connell CL, Liebman HA. Treating venous thromboembolism in patients with cancer. Expert Rev Hematol 2012;5(2):201-9.   DOI
78 Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012;366(9):864-6.   DOI
79 King AE, Szarlej DK, Rincon F. Dabigatran-associated intracranial hemorrhage: literature review and institutional experience. Neurohospitalist 2015;5(4):234-44.   DOI
80 Wychowski MK and Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother 2012;46(4):e10.
81 Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. Thromb Haemost 2012;108(2):217-24.   DOI
82 Riechelmann RP and Del Giglio A. Drug interactions in oncology: how common are they? Ann Oncol 2009;. doi: 10.1093/annonc/mdp369.   DOI
83 Caliskan F, Akdemir HU, Nurata H, et al. Rivaroxaban-induced severe diffuse intracerebral hemorrhage. Am J Emerg Med 2015;33(3):e471.
84 Kato T, Kimura M, Inoko M. Cerebral infarction accompanied by cerebral bleeding in patients receiving apixaban. BMJ Case Rep 2015;2015. doi: 10.1136/bcr-2014-208965.   DOI
85 Molina M, Hillard VH, Fekete R. Intracranial hemorrhage in patient treated with rivaroxaban. Hematol Rep 2014;6(1):5283.
86 Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidencebased clinical practice guidelines. Chest 2012;141(suppl2):e152S-84S.   DOI
87 Steiner T, Bohm M, Dichgans M, et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 2013;102(6):399-412.   DOI
88 Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124(14):1573-9.   DOI
89 Sarich TC, Seltzer JH, Berkowitz SD, et al. Novel oral anticoagulants and reversal agents: Considerations for clinical development. Am Heart J 2015;169(6):751-7.   DOI
90 Suryanarayan D and Schulman S. Potential antidotes for reversal of old and new oral anticoagulants. Thromb Res 2014;133:S158-66.   DOI
91 Lazo-Langner A, Lang ES, Douketis J. Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications. Crit Care 2013;17(3):230.   DOI
92 Faraoni D, Levy JH, Albaladejo P, et al. Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants. Crit Care 2015;19(1):1-6.   DOI
93 Sardar P, Chatterjee S, Chaudhari S, et al. New oral anticoagulants in elderly adults: evidence from a meta-Analysis of randomized trials. J Am Geriatr Soc 2014;62(5):857-64.   DOI
94 Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban for the management of elderly patients with atrial fibrillation: ENGAGE AF-TIMI 48. Circulation 2014;130(suppl2): A16612.
95 Shoeb M and Fang MC. Assessing Bleeding Risk in Patients Taking Anticoagulants. J Thromb Thrombolysis 2013;35(3):312-9.   DOI
96 Prandoni P. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations. Thromb Res 2014;134(2): 227-33.   DOI
97 Bertoletti L, Ollier E, Duvillard C, et al. Direct oral anticoagulants: current indications and unmet needs in the treatment of venous thromboembolism. Pharmacol Res 2016, doi: 10.1016/j.phrs.2016.06.023.   DOI
98 Mauer AC, Khazanov NA, Levenkova N, et al. Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults. J Thromb Haemost 2011;9(1):100-8.   DOI
99 Glund S, Stangier J, Schmohl M, et al. A specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Circulation 2013;128(suppl22):A17765.
100 Schiele F, van Ryn J, Newsome C, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013;121(18): 3554-62.   DOI
101 Schwarb H and Tsakiris DA. New direct oral anticoagulants (DOAC) and their use today. Dent J 2016;4(1):5.   DOI
102 Takach LS, Cohen N, Kearon C. Influence of sex on risk of bleeding in anticoagulated patients: a systematic review and meta-analysis. J Thromb Haemost 2014;12(5):595-605.   DOI
103 Blanco-Molina A, Enea I, Gadelha T, et al. Sex differences in patients receiving anticoagulant therapy for venous thromboembolism. Medicine 2014;93(17):309-17.   DOI
104 Alotaibi GS, Almodaimegh H, McMurtry MS, et al. Do women bleed more than men when prescribed novel oral anticoagulants for venous thromboembolism? A sex-based meta-analysis. Thromb Res 2013; 132(2):185-9.   DOI
105 Glund S, Stangier J, Schmohl M, et al. Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Blood 2014;124(21):344.   DOI
106 Pollack CVJ, Reilly PA, Eikelboom J, et al Idarucizumab for Dabigatran Reversal. N Engl J Med 2015;373(6):511-20.   DOI
107 Siegal DM. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis 2015;39(3):395-402.   DOI
108 Hu TY, Vaidya VR, Asirvatham SJ.Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manage 2016;12:35.
109 Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015;373(25): 2413-24.   DOI
110 Bauer KA. Targeted anti-anticoagulants. N Engl J Med 2015;373(6): 569-71.   DOI
111 Bauersachs RM. Guidelines for the management of cancer and thrombosis - Special aspects in women. Thromb Res 2015;135:S16-22.   DOI
112 Dentali F, Sironi AP, Gianni M, et al. Gender difference in efficacy and safety of nonvitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation or venous thromboembolism: a systematic review and a meta-analysis of the literature. Semin Thromb Hemost 2015;41(17):774-87.   DOI
113 Loffredo L, Violi F, Perri L. Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A metaanalysis of the interventional trials. Int J Cardiol 2016;212:255-8.   DOI
114 Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808.   DOI
115 Upreti VV, Wang J, Barrett YC, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol 2013;76(6):908-16.   DOI
116 Burnett AE, Mahan CE, Vazquez SR, et al. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis 2016;41(1):206-32.   DOI
117 Pokorney SD, Sherwood MW, Becker RC. Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. J Thromb Thrombolysis 2013;36(2):163-74.   DOI
118 Kubitza D, Becka M, Zuehlsdorf M, et al. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007;47(2):218-26.   DOI
119 Lip GY and Agnelli G. Edoxaban: a focused review of its clinical pharmacology. Eur Heart J 2014;35(28):1844-55.   DOI
120 Macedo AF, Bell J, McCarron C, et al. Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink. Thromb Res 2015;136(2):250-60.   DOI
121 Aapro M and Launay-Vacher V. Importance of monitoring renal function in patients with cancer. Cancer Treat Rev 2012;38(3):235-40.   DOI
122 Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management. Cancer 2007;110(6):1376-84.   DOI
123 Lichtman SM, Wildiers H, Launay-Vacher V, et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007;43(1):14-34.   DOI
124 Hughes S, Szeki I, Nash MJ, et al. Anticoagulation in chronic kidney disease patients?the practical aspects. Clin Kidney J 2014;7(5):442-9.   DOI
125 Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014;63(4):321-8.   DOI
126 Stangier J, Rathgen K, Stahle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. Clin Pharmacokinet 2010;49(4):259-68.   DOI
127 Safouris A, Triantafyllou N, Parissis J, et al. The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit?risk ratio. Ther Adv Neurol Disord 2015;8(6):245-54.   DOI
128 Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010;70(5): 703-12.   DOI